

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 October 2024 (03.10.2024)



(10) International Publication Number
WO 2024/206740 A1

(51) International Patent Classification:

A61K 38/22 (2006.01) A61K 45/06 (2006.01)
A61K 38/26 (2006.01) A61P 1/08 (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/022122

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:

29 March 2024 (29.03.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/493,384 31 March 2023 (31.03.2023) US
63/585,493 26 September 2023 (26.09.2023) US

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly
Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **EMMERSON, Paul Joseph**; c/o Eli Lilly and
Company, PO Box 6288, Indianapolis, Indiana 46206-6288
(US). **MATHER, Kieran James**; c/o Eli Lilly and Compa-
ny, PO Box 6288, Indianapolis, Indiana 46206-6288
(US). **PRATT, Edward John**; c/o Eli Lilly and Compa-
ny, PO Box 6288, Indianapolis, Indiana 46206-6288 (US).
ROELL, William Christopher; c/o Eli Lilly and Compa-
ny, PO Box 6288, Indianapolis, Indiana 46206-6288 (US).
SAMMS, Ricardo J.; c/o Eli Lilly and Company, PO Box
6288, Indianapolis, Indiana 46206-6288 (US). **URVA, Sh-
weta**; c/o Eli Lilly and Company, PO Box 6288, Indianapo-
lis, Indiana 46206-6288 (US).

(74) Agent: **REXER, Charles H.** et al.; Eli Lilly and Company,
Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: METHODS AND USES FOR TREATING NAUSEA AND EMESIS

(57) Abstract: GIP receptor agonists of the present disclosure have anti-emetic properties and therefore can be used to reduce or inhibit the frequency or severity of episodes of nausea or emesis in a patient in need thereof.

WO 2024/206740 A1